Complement Dependent Cytotoxicity in Chronic Lymphocytic Leukemia: Ofatumumab Enhances Alemtuzumab Complement Dependent Cytotoxicity and Reveals Cells Resistant to Activated Complement

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2012.681657

Related search